BD, a leading global medical technology company, has announced availability in Europe (CE marked) of the new BD Kiestra™ InoqulA system powered by BD Synapsys™ informatics solution.
The BD Kiestra™ InoqulA, which is available as a standalone instrument for microbiology labs, is a high throughput solution that offers enhanced workflow flexibility allowing the user to seamlessly switch between two modes to process liquid and non-liquid samples, enabling on demand processing of urgent samples and continuous loading and unloading of samples and plates during operation, minimizing interruptions to workflow. The system uses unique rolling-bead technology to generate more discrete colonies than traditional manual loop-based streaking.
“Sample processing has historically been manual, error-prone, and labor-intensive,” said Cecilia Soriano, vice president and general manager of Microbiology at BD. “The BD Kiestra™ InoqulA allows the user to prioritize urgent samples immediately for on-demand processing minimizing workflow interruption. The BD Kiestra™ InoqulA also reduces the need for subculture, which may shorten the time for microbial identification and antibiotic susceptibility testing, allowing earlier result reporting.”
BD Synapsys™ informatics solution is an advanced, secure and scalable platform that provides connectivity for several BD diagnostic instruments, rules-based workflow and on-demand actionable insights to help laboratories impact their performance. BD Kiestra™ InoqulA, powered by BD Synapsys™ informatics solution, supports complete traceability of plates through automatically generated barcodes. Several workflow enhancements—offline inoculation, simplified batch ordering processes, and custom culture protocols can be easily viewed via custom reports in the BD Synapsys™ informatics solution.
Do you use BD Biosciences products in your lab? Write a review today for your chance to win a $400 Amazon gift card>>